US Government As Represented by the Secretary of the Army

Other

Inovio Pharmaceuticals, Inc.

Powerject Vaccines Inc.

U.S. Army Medical Research Institute of Infectious Diseases Department of the Army

Connie S Schmaljohn

Jay Hooper

Alan L Schmaljohn

Mary C Guttieri

Robert F Garry

Niranjan Y Sardesai

Kate Broderick

Peter B Jahrling

David J McClain

Lesley Dupuy

Jeffrey W Koehler

Max Custer

Joel Dalrymple, Deceased

Alan Schmaljohn

Kathleen Cashman

Deborah L Fuller

Joel R Haynes

Joel M Dalrymple

Jay W Hooper

A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.

Gene optimized Hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome

Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome

A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any

The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.

Antiviral rift valley fever virus peptides and methods of use

Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. As disclosed herein, the nucleotide sequences confer protection against Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and/or eastern equine encephalitis virus (EEEV).

Equine encephalitis virus vaccines and methods of using thereof

The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.

Cross-protective arenavirus vaccines and their method of use

Three vectors are described which allow the conversion of Fab fragments into or single chain Fv fragments into full-length antibody molecules. Methods for using the vectors and the resulting antibodies are also described.

Antibodies expressed in insect cells

In this application is described a protective DNA vaccines against infection with HFRS- and HPS-associated hantaviruses. The vaccines were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) into the DNA expression vector pWRG7077. Animals vaccinated with the M construct developed a neutralizing antibody response. Passive transfer experiments show that serum from vaccinated animals, when injected on days 4 or 5 after challenge, protected animals from lethal disease.

Extraneous DNA sequence that facilitates hantavirus gene expression

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Prophylactic and therapeutic monoclonal antibodies

In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.

DNA vaccines against poxviruses

Particle mediated immunization of tick-borne flavivirus genes confers homologous and heterologous protection against tick borne encephalitis.

DNA vaccines against tick-borne flaviviruses

An approach to genetic vaccine methodology is described. A genetic construction encoding antigenic determinants of a filovirus is transfected into cells of the vaccinated individuals using a particle acceleration protocol so as to express the viral antigens in healthy cells to produce an immune response to those antigens.

Genetic induction of anti-viral immune response and genetic vaccine for filovirus

Vaccine formulations for inducing protective immune response to Hantaviruses in humans are disclosed. These formulations include an attenuated vaccinia virus vector containing cDNA's encoding Hantavirus nucleocapsid N protein, G1 and G2 glycoproteins. Methods for the use of these formulations also are disclosed.

Hantavirus vaccine

Nucleotide sequences coding for Hantaan virus nucleocapsid protein and glproteins G1 and G2 can be used to produce these proteins for vaccine and diagnostic applications.

Growing community of inventors

Frederick, MD, United States of America

Connie S Schmaljohn